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1013-68 N-Terminal Brain Natriuretic Peptide: The New Gold 
Standard in Predicting Mortality in Patients With 
Advanced Heart Failure 
Roy S. Gardner. Faruk Ozalp, Andrew J. Murday, Stephen D. Robb, Theresa A. 
McDonagh. University of Glasgow, Glasgow, United Kingdom 
Background. Selection of patients for cardiac transplantation is difficult and has tradi- 
tionally relied upon assessing clinical status as well as parameters of LV dysfunction 
associated with an adverse outcome such as the left ventricular ejection fraction (LVEF), 
maximum oxygen uptake (VC& “ax) and more recently, composite scoring SyStSmS e.g. 
the heart failure suwival score (HFSS). Brain natriuretic peptide (BNP) is well established 
as an independent predictor of prognosis in mild to moderate chronic heart failure (CHF). 
However, the prognostic ability of NT-proBNP in advanced heart failure is unknown and 
no studies have compared NT-proBNP to standard clinical markers used in the selection 
of patients for transplantation. This study describes the prognostic ability of NT-proBNP 
and compares it to that of the LVEF, VC$ max and the HFSS in a coholt of patients 
referred for cardiac transplantation. 
Methods We prospectively studied 128 consecutive patients with advanced CHF 
referred for consideration of cardiac transplantation. Blood for NT-proBNP analysis was 
sampled at recruitment and patients followed up for a mean of 280 days. We report on 
the primary endpoint of all cause mortality and the secondary one of all Cause morlality or 
urgent cardiac transplantation. 
Results The median N-BNP was 1498pg/ml [inter-quartile range 544-38831. The only 
univariate and multivariate predictor of all cause mortality was an NT-proBNP level 
above the median value (R&5.0 [1.7-22.41, p=O.O02). The univariate predictors of all 
cause mortality or urgent cardiac transplantation were: a RVEF<median (RR=3), a 
HFSS<median (RR=3) and serum sodiumcmedian (RR=4.3) and NT-proBNPzmedian 
(RR=@. The only Independent predictors of all cause mortality or urgent cardiac trans- 
plantation were an NT-proBNP value>median (RR=6.9 [2.0-23.71. p=O.OOZ) and a serum 
sodium concentratkxxmedian value (RR=4.4 [l.l-9.71, p=O.O4). LVEF, VQ and HFSS 
were not independently predictive of mortality in this study. 
Conclusions. A single measurement of NT-proBNP in patients with advanced CHF can 
help to identify patients at the highest risk of death, and is a better prognostic marker 
than LVEF, VQ or HFSS. 
1013-69 Relationship Between Serial Measurements of N- 
Terminal Pro-Brain Natriuretic Peptide and Ambulatory 
Cardiac Filling Pressures in Outpatients With Heart 
Failure 
Frieder Braunschwelq, Astrid Fahrleitner, Stefano Ghio, Maurizio Manglavacchi, Parwis 
Fotuhi. Uta C. Hoppe, Mark Harrison, Cecila Linde. Karolinska Hospital, Stockholm, 
Sweden 
Background: Plasma levels of N-terminal pro brain natriuretic peptide (NT-proBNP) are 
thought to reflect the hemodynamic state and may be useful in the management of out- 
patients with chronic heart failure (CHF). We used an implanted hemodynamic monitor 
(IHM) to study the relationship between serial measurements of plasma NT-proBNP lev- 
els and ambulatory cardiac filling pressures. 
Methods: 13 pt with CHF (58 f 10 y; LVEF 24 + 8%; LVEDD 69 * 13 mm) with an IHM, 
(Chronicle@, Medtronic lnc) were included. The ambulatory right ventricular systolic pres- 
sure (RVSP) and estimated diastolic pulmonary altery pressure (ePAD) were sampled 
continuously and expressed as the 24 hour median preceding each blwd sample. Three 
to six blood samples for analysis of plasma NT-proBNP (ELISA, Biomedica, normal 
range < 250 fmollml) were taken in each patient with a minimum interval of two weeks in 
between. Intra-patient correlations between serial NT-proBNP measurements and the 
corresponding filling pressures were calculated using a random coefficient model (proce- 
dure Mixed in SAS). 
Results: NT-proBNP plasma levels were elevated in all cases (range 522-1696 fmollml) 
but varied largely between patients. Accordingly, the individual means of NT-proBNP and 
hemodvnamic parameters were not correlated (r=O.lZ and 0.13 for RVSP and ePAD 
respectively). However, serial measurements in the individual patients yielded significant 
positive intra-oat&t correlations between NT-!xoBNP and RVSP imedian r=0.71. 
p=O.O06) and ePAD (median r=O.71, p= 0.001). respectively. 
Conclusion: In outpatients with chronic heart failure, serial measurements of NT-proBNP 
in the same Individual correlate significantly with hemodynamic parameters and reflect 
changes of the hemodynamic state over time, despite a large variation of NT-proBNP 
plasma levels between patients. This finding supports the hypothesis, that serial mea- 
surements of NT-proBNP may be a useful tool for outpatient management in chronic 
heart failure. 
1013-70 Neurohumoral Changes as Markers of Progressive Left 
Ventricular Remodeling in Systolic Heart Failure: 
Results of the Neurohumoral Substudy of the 
Randomized Evaluation of Strategies for Left 
Ventricular Dysfunction (RESOLVD) 
Raymond T. Yan, Rizwan Afzal, Robert McKelvie, McMaster University and Hamilton 
Health Sciences, Hamilton, ON, Canada 
Background:Various neurohormones (NH) are reported as useful diagnostic markers of 
heart failure (HF) and have been shown previously to correlate with baseline left venttic- 
ular ejection fraction (LVEF) and volumes. However, the relationships between temporal 
changes in these NH and progressive cardiac remodeling in chronic HF have not been 
studied. 
Methods: We evaluated 677 subjects with baseline LVEF 28*10% (mean&D) enrolled 
in RESOLVD, a P-phase 3x2 factorial randomized study of the efficacy of candersartan at 
various doses and metoprolol in addition to enalapril in systolic HF. Serial changes in 
LVEF (1.8+6.9%). end-diastolic volume (EDV 18t60ml), and end-systolic volume (ESV 
9*53ml) measured by radionuclide ventriculography between baseline and end of phase 
II (week 42) wars correlated with time correspondent changes in brain natriuretic peptide 
(BNP), N-terminal proatrial natriuretic peptide (NBANP), angiotensin II, aldostsrone, 
endothelin I, norepinephrine and epinephrine. 
Results: Among all measured NH, only changes in BNP and Nt-ANP were significantly 
correlated with changes in EDV. ESV and LVEF consistently irrespective of study phase 
and therapy as summarized below: 
Pearson Co&i&m for Changes Between End of Phase II (week 42) and Baseline 
Pearson Coefficients: 
All subjects (N=677) 
‘P = 0.01 
“P < 0.0001 
Changes in ESV Changes in EDV Changes in LVEF 
BNP changes 
Nt-ANP Changes 
Angiotensin II Changes 
Aldosterone Changes 
Endothelin I Changes 
+ 0.24 ** + 0.24 ** - 0.18 ** 
+ 0.25 ** + 0.23 ** - 0.10 * 
- 0.03 - 0.04 + 0.01 
+ 0.03 + 0.06 - 0.07 
- 0.03 - 0.03 
O.&l 
Norepinephrine Changes + 0.02 + 0.04 - 0.03 
Epinephrine Changes - 0.02 - 0.03 0.02 
Conclusions In this shalt-term study, serial increases in BNP and Nt-ANP levels pre- 
dicted ongoing adverse LV remodeling evidenced by declining LVEF, increasing EDV 
and ESV. Serial measurements of these NH may serve as useful clinical markers for high 
risk HF patients in whom more aggressive therapy may be warranted. 
1013-71 Plasma Norepinephrine Predicts la-Year Survival in 
Patlents With Reduced Ejection Fractions From the 
Studies of Left Ventricular Dysfunction (SOLVD) 
Philip Jong. Michel F. Rousseau, Sylvie A. Ahn, Shrikant I. Bangdiwala, Claude R. 
Benedict, Salim Yusuf, M&taster University, Hamilton, ON, Canada 
Background: In the Studies Of Left Ventricular Dysfunction (SOLVD), plasma norepi- 
nephrine (PNE) was shown to predict in-trial survival among patients with reduced ejec- 
tion fractions. We examined whether PNE and other neurohormones would also predict 
long-term suwival during a post-trial follow-up of SOLVD. 
Methods: PNE (n = 730), plasma renin activity (n = 731), atrial natriuretic peptide (n = 
366), and arginine vasopressin (n = 364) were measured at baseline in subsets of 6797 
patients previously enrolled in SOLVD. Risk-adjusted suwival at 12 years after trial 
enrollment was compared between patients whose neurohormonal levels lied above and 
below the group median values. 
Results: PNE was the strongest neurohormonal predictor of 12.year swvival. After 
adjusting for age, sex, ejection fraction, cause of heart failure, functional class, treatment 
and trial assignments, PNE levels above the median of 409 pgiml were associated with a 
36% relative hazard increase in all-cause mortality (95% Cl 11 to 66%, p = 0.003) and a 
42% relative hazard increase in cardiac mortality (95% Cl 13 to 79%, p = 0.003), as com- 
pared with levels below the median (Figures). Increases in the levels of the other neuro- 
hormones were not predictive of all-cause mortality in the long term. 
Conclusfon: Elevated PNE remains a powerful and independent predictor of increased 
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1 P-year all-cause and cardiac mortalities in patients with left ventricular systolic dysfunc- 
tion, including those without overt heart failure at baseline. 
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The data from this retrospective analysis of RITZ-4 suggest that an elevated cTn I on 
admission in patients with acute ischemic HF is associated with a higher short-term risk 
of death, worsening heart failure, or recurrent or new ischemia or Ml. These results sug- 
gest that ischemia and myocyte necrosis is important prognostically in the setting of 
acute HF and is likely a significant contributor to worse outcomes. cTn may be a useful 
prognostic marker or risk stratification tool in future clinical HF trials and potentially clini- 
cal practice, particularly in patients with underlying ischemic heart disease. 
1013-74 Predictors of Mortality After Hospitalization for 
Decompensated Heart Failure 
Doron Aronson. Darlene P. Horton. Andrew J. Burger, Rambam Medical Center, Halfa, 
Israel, Beth Israel Deaconess Medical Center, Boston, MA 
Background: Hospitalization for decompensated heart failure (HF) is associated with a 
high mortality after discharge. Despite the large number of hospital admissions for HF, lit- 
tle data are available on the outcome of such patients after hospital discharge. 
Methods: The effect of baseline clinical parameters on mortality was evaluated in 560 
patients (mean age 63 * 14 years, 377 male) with a previous diagnosis of HF (96% with 
NYHA class Ill or IV) who ware admitted for decompensated HF. 
Results: During a mean follow-up of 343 f 185 days, 177 patients (32%) died. A Cox 
proportional-hazards model, adjusted for age, gender, diabetes, primary etiology of HF 
stratified as ischemic or nonischemic, sodium, blood urea nitrogen (BUN), creatinine, and 
medical therapy (ACE inhibitors, P-blockers, digoxin, and amiodarone) identified the fol- 
lowing variables as predictors of increased mortality: age > 65y (RR = 1.5, 95% Cl 1.1. 
2.1, p = O.Ol), ischemic HF (RR = 1.8, 95% Cl 1.3-2.6, p = O.OOl), sodium 2 135 (RR = 
1.8, 95% Cl 1.3-2.5, p = 0.004) and elevated BUN. The risk of death increased continu- 
ously with each quartile of BUN (Figure), with a 3-fold increase in mortality in patients in 
the upper compared to the lower quartile of BUN (95% Cl 1 7-5.3, p = 0.0003). Creatinine 
was not a predictor of mortality after adjustment for other covariates. 
Conclusion: Simple clinical variables provide useful prognostic information in patients 
with decompensated HF. BUN appears to be the most powerful predictor of post-dis- 
charge outcome. 
1013-72 Limited Diagnostic Accuracy of B-Type Natriuretic 
Peptide to Predict Cardiac Filling Pressures in Patients 
Treated for Severe Congestive Heart Failure 
William A. Parsona% Julia Potter, Gus Koerbin. Andrew J. Galbraith, The Prince 
Charles Hospital, Brisbane. Australia 
Background: Measurement of plasma B- type natriuretic peptide (BNP) is a novel and 
accurate non-invasive method of diagnosing congestive heart failure (CHF) in patients 
presenting with dyspnoea. In view of the relationship between BNP and elevated cardiac 
filling pressures it has been suggested that BNP may be used to guide therapy in 
patients with established CHF. However the accuracy of BNP for predicting filling pres- 
sures in patients receiving conventional medical treatment for severe CHF has not been 
well documented. We studied this relationship in a large cohort of patients. 
Method: We sampled blood for measurement of BNP in 76 patients with severe CHF 
immediately prior to right heart cathetedsation. Plasma BNP was measured using the 
commercially available Triage BNP@ fluorescent immunoassay (Biosite Diagnostics, 
Velozy, France). Diagnostic accuracy and the predictive value of BNP for a pulmonary 
capillary wedge pressure (PCWP) of >15mmHg was calculated in the usual way to deter- 
mine the most accurate cut off value for BNP. 
Results: Patients had severe CHF indicated by a mean PCWP of 20+12mmHg and car- 
diac index of 2.4*0.7lJmin/n?. despite the fact that >r30% were on treatment inhlbitmg the 
renin-angiotansin system and 36% ware taking a beta blocker. A BNP of >lOOpglml gave 
a sensitivity of 56% and a specificity of 91% for PCWP >15mmHg. The negative predic- 
tive value of this level for a PCWP, 15mmHg was 64% and the diagnostic accuracy 72%. 
Conclusion: This is the largest study validating a commercially available BNP assay 
against invasively measured hemodynamics in a cohort of patients with severe CHF 
despite conventional treatment. In this cohort the diagnostic accuracy of BNP for prog- 
nostically important elevation of PCWP is limited. Relying on BNP alone to guide therapy 
would lead to underestimation of PCWP in over a third of patients. It is possible that the 
relationship between PCWP and BNP is confounded by conventional CHF treatment or 
that the relationship simply breaks down at the severe extreme of the disease spectrum. 
Our results suggest that there may be limitations to the use of BNP guided therapy III 
patients with CHF. 
1013-73 Elevated Troponin I Predicts Clinical Events in Patients 
Admitted With Acute Heart Failure: Insights From the 
RITZ-4 Trial 
Christopher M. O’Connor, Wendy A. Gattis, Vie Hasselblad, Isaac Kobrin, Kirkwood F. 
Adams, Jr., Mihai Gheorghiade, Duke Clinical Research Institute. Durham, NC, Actelion. 
Ltd., Basel, Switzerland 
Background: Cardiac troponins (cTn) are important prognostic indicators in patients with 
acute coronary syndrome (ACS) and may be useful for risk stratifying patients with heart 
failure (HF). Few data are available to describe patients with ACS in the setting of acute 
HF. The relationship of cTn to clinical outcomes has not been described in this patient 
population. The purpose of this analysis was to characterze the relationship of cTn I and 
clinical outcomes among patients with acute ischemic HF enrolled Into the RITZ-4 study. 
Methods: RITZ-4 was a multi-center, randomized, double-blind, placebo controlled trial of 
the endothelin receptor antagonist tezosentan in patients admitted with ACS and acute 
HF. 193 patients were enrolled in this study. ACS was defined by ECG changes, or CK, 
CKMB, cTn T. or cTn I. The primary endpoint of RITZ-4 was the combined incidence of 
death, worsening HF, or recurrent or new ischemia or MI, within 72 hours after random- 
ization. Patients with baseline cTn I values were included in this analysis. Results: 133 
patients had values for cTn I at admission in RITZ-4 and were included in this analysis. 
The median (2d”. 75’7 age of this population was 68.5 (56, 76) years. The population 
was 51% men. and 72% were Caucasian. Forty-two patients had cTn I < 1.0 nglmL and 
91 patients had cTn I Z 1 .O ng/mL. Patients with cTn I _> 1 .O ng/mL had a higher lrw- 
dence of the composite primary endpoint as compared to patients with cTn I < 1 .O ng/mL, 
28.6% vs 23.8%, respectively, odds ratio 1.15, 95% Cl 1.01-1.32, p=O.O4. 
Conclusions: 
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1013-75 Uncovering Heart Failure in Patients With 
Bronchospasm: Rationale for the Early Use of B-Type 
Natriuretic Peptide in the Emergency Department 
PeterA. McCullough, Torbjorn Omland, Catherine W. Knudsen, Philippe Due, Richard M. 
Nowak. James McCord, Judd E. Hollander, Marie-Claude Aumont. Philippe Gabriel Steg. 
Arne Westheim, Alan B. Storrow, William T. Abraham, Sumant Lamba, Alan H. Wu, Alan 
S. Maisel, BNP Multinational Study Investigators, William Beaumont Hospital, Royal 
Oak, MI. University of California, San Diego School of Medicine, Veterans Affairs Medical 
Center, San Diego, CA 
Introduction: Plasma B-type natriuretic peptide (BNP) determination can be used to reli- 
ably identify patients with acute congestive heart failure (CHF) in patients presenting in 
the emergency department (ED) with acute dyspnea. Impaired left ventricular (LV) sys- 
tolic and diastolic function as well as increased left ventricular (LV) mass are asssociated 
with increased circulating BNP levels. Heart failure, asthma, chronic obstructive pulmo- 
nary disease (COPD). and other bronchospastic disorders, are syndromes where dysp- 
nea and wheezing are overlapping signs, and hence, these syndromes are often diflicult 
to differentiate. 
Methods The BNP Multinational Study was a seven-center prospective study of 1586 
patients presenting to the ED with acute dyspnea and had blinded BNP levels measured 
wth a rapid, point-of-care device on arrival. The reference standard for CHF was adjudi- 
cated by two independent cardiologists, also blinded to BNP results, who reviewed all 
clinical data and standardized CHF scores. 
Results A total of 417 subjects (mean age 62.2 years, 64.4% male) had a history of 
asthma or COPD without a history of CHF. Of these, 871417 (20.9%, 95% Cl 17.1. 
25.1%) were found to have CHF as the final adjudicated dlagnosls. The ED physicians 
identified 32/87 (36.8%) as having CHF. The mean BNP values ware 587.0 and 108.8 
pglml for those with and without CHF, p < 0.0001. If BNP would have been added to clin- 
ical judgement, at a cutpomt of 100 pglml. 83187 (95.4%) of CHF subjects would have 
been correctly diagnosed. In the 87 subjects who were found to have CHF, 39.0, 22.2, 
and 54.8% were taking angiotensin converting enzyme mhlbitors (ACEI), beta-blockers 
(BB). and diuretics on a chronic basis, respectively. 
Conclusion: The yield of adding routine BNP testing in patients with a history of asthma 
